Abstract:Background Pencil beam scanning (PBS) proton therapy for moving targets is known to be impacted by interplay effects between the scanning beam and organ motion. While respiratory motion in the thoracic region is the major cause for organ motion, interplay effects depend on the delivery characteristics of proton accelerators. Purpose To evaluate the impact of different types of PBS proton accelerators and spot sizes on interplay effects, mitigations, and plan quality for Stereotactic Body Radiation Therapy (SBRT) treatment of non‐small cell lung cancer (NSCLC). Methods Twenty NSCLC patients treated with photon SBRT were selected to represent varying tumor volumes and respiratory motion amplitudes (median: 0.6 cm with abdominal compression) for this retrospective study. For each patient, plans were created using: (1) cyclotron‐generated proton beams (CPB) with spot sizes of σ = 2.7–7.0 mm; (2) linear accelerator proton beams (LPB) (σ = 2.9–5.5 mm); and (3) linear accelerator proton minibeams (LPMB) (σ = 0.9–3.9 mm). The energy switching time is one second for CPB, and 0.005 s for LPMB and LPB. Plans were robustly optimized on the gross tumor volume (GTV) using each individual phase of four‐dimensional computed tomography (4DCT) scans. Initially, single‐field optimization (SFO) plans were evaluated; if the plan quality did not meet the dosimetric requirement, multi‐field optimization (MFO) was used. MFO plans were created for all patients for comparisons. For each patient, all plans were normalized to have the same dose received by 99% of the GTV. Interplay effects were evaluated by computing the dose on 10 breathing phases, based on the spot distribution. Volumetric repainting (VR) was performed 2–6 times for each plan. We compared volume receiving 100% of the prescribed dose (V100%RX) of the GTV, and normal lung V20Gy. Results Twelve of 20 plans can be optimized sufficiently with SFO. SFO plans were less sensitive to the interplay effect compared to MFO plans in terms of target coverage for both LPB and LPMB. The following comparisons showed results utilizing the MFO technique. In the interplay evaluation without repainting, the mean V100%RX of the GTV were 99.42 ± 0.6%, 97.52 ± 3.9%, and 94.49 ± 7.3% for CPB, LPB, and LPMB plans, respectively. Following VR (2 × for CPB; 3 × for LPB; 5 × for LPMB), V100%RX of the GTV were improved (on average) by 0.13%, 1.84%, and 4.63%, respectively, achieving the acceptance criteria of V100%RX > 95%. Because of fast energy switch in linear accelerator proton machines, the delivery time for VR plans was the lowest for LPB plans, while delivery time for LPMB was on average 1 min longer than CPB plans. The advantage of small spot machines was better sparing in normal lung V20Gy, even when VR was applied. Conclusion In the absence of repainting, proton machines with large spot sizes generated more robust plans against interplay effects. The number of VR increased with decreasing spot sizes to achieve the acceptance criteria. VR improved the plan robustness against interplay effects for modalities with small spot sizes and fast energy changes, preserving the low dose sparing aspect of the LPMB, even when motion is included.

Evaluation and Mitigation of the Interplay Effects of Intensity Modulated Proton Therapy for Lung Cancer in a Clinical Setting.

Impact Of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy And Vmat Delivery For Prostate Cancer

On the interplay effects with proton scanning beams in stage III lung cancer.

Impact of interplay effects on spot scanning proton therapy with motion mitigation techniques for lung cancer: SFUD versus robustly optimized IMPT plans utilizing a four-dimensional dynamic dose simulation tool

Intensity-modulated Proton Therapy (IMPT) Interplay Effect Evaluation of Asymmetric Breathing with Simultaneous Uncertainty Considerations in Patients with Non-Small Cell Lung Cancer.

Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic Malignancies.

Mitigation of the Interplay Effects of Combining 4D Robust With Layer Repainting Techniques in Proton-Based SBRT for Patients With Early-Stage Non-small Cell Lung Cancer

Evaluation Of The Dosimetric Impact Of Interfractional Anatomical Variations On Prostate Proton Therapy Using Daily In-Room Ct Images

Impact of proton PBS machine operating parameters on the effectiveness of layer rescanning for interplay effect mitigation in lung SBRT treatment

Interplay effect on a 6-MV flattening-filter-free linear accelerator with high dose rate and fast multi-leaf collimator motion treating breast and lung phantoms

Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer.

Intensity-modulated Proton Therapy Reduces the Dose to Normal Tissue Compared with Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-cell Lung Cancer: a Virtual Clinical Study.

Cyclotron and linear accelerator generated scanning proton beams for lung cancer SBRT: Interplay effects and mitigations

Proton energy optimization and reduction for intensity-modulated proton therapy.

Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy

Exploring the Advantages of Intensity-Modulated Proton Therapy: Experimental Validation of Biological Effects Using Two Different Beam Intensity-Modulation Patterns

Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers.

Effect of Setup and Inter-Fraction Anatomical Changes on the Accumulated Dose in CT-guided Breath-Hold Intensity Modulated Proton Therapy of Liver Malignancies.

An efficient dose calculation strategy for intensity modulated proton therapy.

Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC

Dosimetric Comparison of Intensity-Modulated Proton Radiotherapy Versus Intensity-Modulated Photon-Based Radiotherapy for Breast Cancer